News | October 15, 2014

RSNA Receives NIBIB Funding for QIBA Research

RSNA has received an additional $1.27 million of funding from the National Institute of Biomedical Imaging and Bioengineering to support research by the Quantitative Imaging Biomarkers Alliance

October 15, 2014 – The Radiological Society of North America (RSNA) has received an additional $1.27 million of funding from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) to support research by the Quantitative Imaging Biomarkers Alliance (QIBA). This marks the fourth consecutive year that NIBIB has funded research groundwork by QIBA, following a 2013 contract for $1.25 million.

Quantitative imaging is the extraction of quantifiable features from medical images for the assessment of normal or the severity, degree of change or status of a disease, injury or chronic condition relative to normal.

Quantitative imaging includes the development, standardization and optimization of anatomical, functional and molecular imaging acquisition protocols, data analyses, display methods and reporting structures. These features permit the validation of accurately and precisely obtained image-derived metrics with anatomically and physiologically relevant parameters, including treatment response and outcome, and the use of such metrics in research and patient care.

QIBA is an initiative organized by RSNA in 2007 to advance quantitative imaging and the use of imaging biomarkers in clinical trials and practice.

QIBA engages researchers, healthcare professionals and industry stakeholders by collaborating to identify needs, barriers and solutions to develop and test consistent, reliable, valid and achievable quantitative imaging results across imaging platforms, clinical sites and time. QIBA also works to accelerate the development and adoption of hardware and software standards needed to achieve accurate and reproducible quantitative results from imaging methods.

A portion of the new NIBIB award has been earmarked to support QIBA projects and activities, including development of a Quantitative Imaging Data Warehouse, research to characterize the sources of bias and achievable precision associated with quantitative imaging, and to further develop and test phantoms and digital reference objects.

 

“We are honored and gratified that NIBIB continues to recognize the importance of objective, quantitative results from imaging studies to patient care, and provides ongoing support for QIBA’s foundational work in this effort,” said Daniel C. Sullivan, M.D., QIBA Chair.

 

For more information visit: www.rsna.org

Related Content

PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...
TriHealth in Cincinnati

TriHealth in Cincinnati.

Sponsored Content | Case Study | Contrast Media Injectors | March 06, 2018
The continuing search for advantages to improve workflow has radiology departments constantly searching for new...
Guerbet Presents Contrast&Care Injection Management Solution at ECR 2018
News | Contrast Media | February 28, 2018
February 28, 2018 — Guerbet will present its new Contrast&Care application, as well as other...
Overlay Init